Immunovaccine Inc.

Immunovaccine Inc.

September 01, 2016 07:05 ET

Immunovaccine to Present at 2016 Rodman & Renshaw Global Investment Conference

HALIFAX, NOVA SCOTIA--(Marketwired - Sept. 1, 2016) - Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced that it will participate in the 18th Annual Rodman & Renshaw Global Investment Conference taking place from September 11-13, 2016 at the Lotte New York Palace Hotel in New York, New York.

Chief Executive Officer Frederic Ors is scheduled to present an overview of the Company's recent progress and future strategy on Monday, September 12, at 10:25 a.m. ET in the Adams Room on the fourth floor of the Lotte New York Palace Hotel. To arrange a meeting with management, please contact Danielle Evans at or visit this link to schedule a one-on-one directly.

The presentation will be available on Immunovaccine's website at following the meeting.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). In collaboration with commercial and academic partners, Immunovaccine is also expanding the application of DepoVax™ as an adjuvanting platform for vaccines targeted against infectious diseases. Immunovaccine's goal in infectious diseases is to out-license its DepoVax™ platform to partners to generate earlier revenues. Connect at

Immunovaccine Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Contact Information